WO2026062585 - METHODS OF TREATMENT USING ANTI-TREM2 ANTIBODIES
National phase entry is expected:
Publication Number
WO/2026/062585
Publication Date
26.03.2026
International Application No.
PCT/IB2025/059459
International Filing Date
19.09.2025
Title **
[English]
METHODS OF TREATMENT USING ANTI-TREM2 ANTIBODIES
[French]
MÉTHODES DE TRAITEMENT UTILISANT DES ANTICORPS ANTI-TREM2
Applicants **
NOVARTIS AG
Inventors
FEUERBACH, Dominik
PERAUS, Gisela
GRAF, Ana
BRUIJN, Lucie Igminia
AGOROPOULOU, Catherine
SERBAN, Carmen
IYER, Shwetha
Priority Data
63/697,131
20.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6846 | |
| EPO | Filing, Examination, Granting | 135643 | |
| Japan | Filing, Examination, Granting | 5014 | |
| South Korea | Filing, Examination, Granting | 9001 | |
| USA | Filing, Examination, Granting | 37140 |
Total:
193,644
Contact Us
Abstract[English]
Methods, treatment regimens, uses, kits and therapies for treating neurological and neurodegenerative disorders, by administering anti-TREM2 antibodies, are disclosed.[French]
L'invention concerne des méthodes, des schémas thérapeutiques, des utilisations, des kits et des thérapies pour traiter des troubles neurologiques et neurodégénératifs, par administration d'anticorps anti-TREM2.